| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
159,588 |
261,929 |
319,053 |
656,089 |
| Total Sell Value |
$13,270,852 |
$22,448,451 |
$27,661,182 |
$61,420,002 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
10 |
20 |
27 |
56 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Aselage Steve |
SVP, Global Commercial Dev |
• – – |
2008-04-01 |
4 |
AS |
$35.75 |
$29,024 |
D/D |
(805) |
32,034 |
|
- |
|
| Aselage Steve |
SVP, Global Commercial Dev |
• – – |
2008-04-01 |
4 |
OE |
$7.16 |
$5,764 |
D/D |
805 |
32,839 |
|
- |
|
| Swiedler Stuart J |
SVP, Clinical Affairs |
• – – |
2008-04-01 |
4 |
AS |
$35.76 |
$450,209 |
D/D |
(12,500) |
10,000 |
|
- |
|
| Swiedler Stuart J |
SVP, Clinical Affairs |
• – – |
2008-04-01 |
4 |
OE |
$6.13 |
$76,625 |
D/D |
12,500 |
22,500 |
|
- |
|
| Kakkis Emil D |
Chief Medical Officer |
• – – |
2008-04-01 |
4 |
AS |
$35.71 |
$353,835 |
D/D |
(9,857) |
86,164 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-25 |
4 |
AS |
$36.04 |
$409,276 |
D/D |
(11,309) |
34,680 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-25 |
4 |
AS |
$35.70 |
$508,975 |
D/D |
(14,189) |
45,989 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-25 |
4 |
AS |
$35.32 |
$337,476 |
D/D |
(9,500) |
60,178 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-25 |
4 |
OE |
$7.76 |
$309,603 |
D/D |
34,998 |
69,678 |
|
- |
|
| Wood Mark |
VP, Human Resources |
• – – |
2008-03-24 |
4 |
AS |
$34.00 |
$104,758 |
D/D |
(2,989) |
0 |
|
- |
|
| Wood Mark |
VP, Human Resources |
• – – |
2008-03-24 |
4 |
OE |
$6.13 |
$40,330 |
D/D |
2,989 |
2,989 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-18 |
4 |
AS |
$31.76 |
$389,686 |
D/D |
(12,128) |
68,792 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-18 |
4 |
OE |
$12.10 |
$559,504 |
D/D |
46,240 |
80,920 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-18 |
4 |
AS |
$32.61 |
$248,080 |
D/D |
(7,576) |
34,680 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-18 |
4 |
AS |
$32.31 |
$861,311 |
D/D |
(26,536) |
42,256 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-14 |
4 |
AS |
$34.14 |
$228,074 |
D/D |
(6,643) |
34,680 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-14 |
4 |
AS |
$33.28 |
$401,578 |
D/D |
(11,957) |
41,323 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-14 |
4 |
AS |
$32.55 |
$229,677 |
D/D |
(7,000) |
65,923 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-14 |
4 |
OE |
$9.50 |
$363,309 |
D/D |
38,243 |
72,923 |
|
- |
|
| Baffi Robert |
SVP, Technical Operations |
• – – |
2008-03-14 |
4 |
AS |
$33.03 |
$419,108 |
D/D |
(12,643) |
53,280 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2008-03-06 |
4 |
S |
$38.28 |
$139,492 |
D/D |
(3,638) |
30,000 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2008-03-06 |
4 |
S |
$37.86 |
$626,968 |
D/D |
(16,451) |
33,638 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2008-03-06 |
4 |
S |
$37.47 |
$373,681 |
D/D |
(9,911) |
50,089 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2008-03-06 |
4 |
OE |
$5.12 |
$465,000 |
D/D |
60,000 |
60,000 |
|
- |
|
| Kakkis Emil D |
Chief Medical Officer |
• – – |
2008-03-06 |
4 |
AS |
$37.99 |
$686,870 |
D/D |
(18,000) |
86,164 |
|
- |
|
1303 Records found
|
|
Page 44 of 53 |
|
|
1.44 (1.6%) 
